Melillo Rosa Marina, Cirafici Anna Maria, De Falco Valentina, Bellantoni Marie, Chiappetta Gennaro, Fusco Alfredo, Carlomagno Francesca, Picascia Antonella, Tramontano Donatella, Tallini Giovanni, Santoro Massimo
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II", via S. Pansini 5, 80131 Naples, Italy.
Am J Pathol. 2004 Aug;165(2):511-21. doi: 10.1016/S0002-9440(10)63316-0.
Activating germ-line point mutations in the RET receptor are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma (MTC), whereas somatic RET rearrangements are prevalent in papillary thyroid carcinomas (PTCs). Some rare kindreds, carrying point mutations in RET, are affected by both cancer types, suggesting that, under specific circumstances, point mutations in RET can drive the generation of PTC. Here we describe a family whose siblings, affected by both PTC and MTC, carried a germ-line point mutation in the RET extracellular domain, converting cysteine 634 into serine. We tested on thyroid follicular cells the transforming activity of RET(C634S), RET(K603Q), another mutant identified in a kindred with both PTC and MTC, RET(C634R) a commonly isolated allele in MEN2A, RET(M918T) responsible for MEN2B and also identified in kindreds with both PTC and MTC, and RET/PTC1 the rearranged oncogene that characterizes bona fide PTC in patients without MTC. We show that the various RET point mutants, but not wild-type RET, scored constitutive kinase activity and exerted mitogenic effects for thyroid PC Cl 3 cells, albeit at significantly lower levels compared to RET/PTC1. The low mitogenic activity of RET point mutants paralleled their reduced kinase activity compared to RET/PTC. Furthermore, RET point mutants maintained a protein domain, the intracellular juxtamembrane domain, that exerted negative effects on the mitogenic activity. In conclusion, RET point mutants can behave as dominant oncogenes for thyroid follicular cells. Their transforming activity, however, is rather modest, providing a possible explanation for the rare association of MTC with PTC.
RET 受体中的种系激活点突变导致 2 型多发性内分泌肿瘤相关的甲状腺髓样癌(MTC),而体细胞 RET 重排在甲状腺乳头状癌(PTC)中很常见。一些携带 RET 点突变的罕见家族同时患有这两种癌症,这表明在特定情况下,RET 点突变可驱动 PTC 的发生。在此,我们描述了一个家族,其兄弟姐妹同时患有 PTC 和 MTC,他们在 RET 细胞外结构域携带种系点突变,将半胱氨酸 634 转化为丝氨酸。我们在甲状腺滤泡细胞上测试了 RET(C634S)、RET(K603Q)(在一个同时患有 PTC 和 MTC 的家族中鉴定出的另一个突变体)、RET(C634R)(MEN2A 中常见的分离等位基因)、RET(M918T)(导致 MEN2B 且在同时患有 PTC 和 MTC 的家族中也有鉴定)以及 RET/PTC1(在无 MTC 的患者中表征真正 PTC 的重排癌基因)的转化活性。我们发现,各种 RET 点突变体(而非野生型 RET)具有组成性激酶活性,并对甲状腺 PC Cl 3 细胞发挥促有丝分裂作用,尽管与 RET/PTC1 相比水平显著较低。RET 点突变体的低促有丝分裂活性与其与 RET/PTC 相比降低的激酶活性平行。此外,RET 点突变体保留了一个蛋白结构域,即细胞内近膜结构域,该结构域对促有丝分裂活性产生负面影响。总之,RET 点突变体可作为甲状腺滤泡细胞的显性癌基因。然而,它们的转化活性相当有限,这可能解释了 MTC 与 PTC 罕见关联的原因。